Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Osteoarthritis Market "to Treble by 2024"
September 20, 2016
The osteoarthritis market across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan is forecast to more than treble from $3.25 billion in 2014 to $10.49 billion by 2024, according to research and consulting firm GlobalData.
The company’s report states that the growth can be attributed to the launch of new biologic therapies priced at a substantial premium to small-molecule therapies, the launch of drugs with novel mechanisms of action (MOAs) and disease-modifying effects, the growth of the osteoarthritis population, and recent improvements in imaging techniques to facilitate the development of disease-modifying osteoarthritis drugs.
Recent Videos
Related Content
